JP2023533204A5 - - Google Patents

Info

Publication number
JP2023533204A5
JP2023533204A5 JP2022580102A JP2022580102A JP2023533204A5 JP 2023533204 A5 JP2023533204 A5 JP 2023533204A5 JP 2022580102 A JP2022580102 A JP 2022580102A JP 2022580102 A JP2022580102 A JP 2022580102A JP 2023533204 A5 JP2023533204 A5 JP 2023533204A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
encoded
gene
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039046 external-priority patent/WO2021263081A2/en
Publication of JP2023533204A publication Critical patent/JP2023533204A/ja
Publication of JP2023533204A5 publication Critical patent/JP2023533204A5/ja
Pending legal-status Critical Current

Links

JP2022580102A 2020-06-26 2021-06-25 乳がんワクチン Pending JP2023533204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044675P 2020-06-26 2020-06-26
US63/044,675 2020-06-26
PCT/US2021/039046 WO2021263081A2 (en) 2020-06-26 2021-06-25 Breast cancer vaccine

Publications (2)

Publication Number Publication Date
JP2023533204A JP2023533204A (ja) 2023-08-02
JP2023533204A5 true JP2023533204A5 (cg-RX-API-DMAC7.html) 2024-07-02

Family

ID=79281909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580102A Pending JP2023533204A (ja) 2020-06-26 2021-06-25 乳がんワクチン

Country Status (6)

Country Link
US (1) US20230233656A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171619A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533204A (cg-RX-API-DMAC7.html)
AU (1) AU2021294322A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183774A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021263081A2 (cg-RX-API-DMAC7.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
HUE047898T2 (hu) * 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3297658A1 (en) * 2015-05-18 2018-03-28 OncoQR ML GmbH Her2/neu immunogenic composition
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
CA3026345A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
KR20190123328A (ko) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
RU2020100072A (ru) * 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
IL272546B2 (en) * 2017-08-24 2024-01-01 Bavarian Nordic As Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业(上海)股份有限公司 结合人her2的抗体、其制备方法和用途

Similar Documents

Publication Publication Date Title
US12521431B2 (en) HBV vaccine
CN104271748B9 (zh) 表达异源肿瘤相关抗原的腺病毒
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
US11471527B2 (en) Virus-like particles including HBs-L antigen protein for causing immune response against HBV
CA2293692A1 (en) Methods and reagents for vaccination which generate a cd8 t cell immune response
JP2023524916A (ja) 腫瘍溶解性ウイルスと免疫チェックポイント阻害剤の併用による腫瘍治療
WO2015106697A1 (zh) 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
US20060188991A1 (en) Flexible vaccine assembly and vaccine delivery platform
CA2325566A1 (en) Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
JPS6349077A (ja) ベクターウイルスおよびベクターウイルスを含む薬用組成物
CA2431188A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
Groeneveldt et al. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
JP2002534481A5 (cg-RX-API-DMAC7.html)
Ozkan How close are we to a Covid-19 vaccine
Bolhassani et al. Small heat shock proteins B1 and B6: Which one is the most effective adjuvant in therapeutic HPV vaccine?
CN101015689A (zh) 基于血管紧张素ⅱ的肿瘤多肽疫苗
US20220152168A1 (en) Sequential heterologous boost oncolytic viral immunotherapy
JP7045024B2 (ja) マラリアワクチン
CN1517437B (zh) 特异性治疗肿瘤或胞内感染的疫苗及应用
CN105176957A (zh) 肾癌相关肽和热休克蛋白形成的复合物及其应用
AU2010321731B2 (en) Compositions, methods and uses for poxvirus elements in vaccine constructs
Bauer et al. Recombinant vaccinia virus promising for melanoma treatment